The estimated Net Worth of Lakhmir S Chawla is at least $512 mil dollars as of 29 January 2019. Dr Chawla owns over 3,000 units of La Jolla Pharmaceutical Co stock worth over $32,711 and over the last 9 years he sold LJPC stock worth over $0. In addition, he makes $478,966 as Consultant at La Jolla Pharmaceutical Co.
Dr has made over 4 trades of the La Jolla Pharmaceutical Co stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of LJPC stock worth $16,680 on 29 January 2019.
The largest trade he's ever made was buying 3,000 units of La Jolla Pharmaceutical Co stock on 29 January 2019 worth over $16,680. On average, Dr trades about 93 units every 20 days since 2015. As of 29 January 2019 he still owns at least 5,259 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Dr Chawla stock trades at the bottom of the page.
Dr. Lakhmir S. Chawla is the Consultant at La Jolla Pharmaceutical Co.
As the Consultant of La Jolla Pharmaceutical Co, the total compensation of Dr Chawla at La Jolla Pharmaceutical Co is $478,966. There are 1 executives at La Jolla Pharmaceutical Co getting paid more, with Larry G. Edwards having the highest compensation of $749,170.
Dr Chawla is 50, he's been the Consultant of La Jolla Pharmaceutical Co since . There are 9 older and 2 younger executives at La Jolla Pharmaceutical Co. The oldest executive at La Jolla Pharmaceutical Co. is Robert Rosen, 64, who is the Independent Director.
Lakhmir's mailing address filed with the SEC is 6, 10182 Telesis Ct, San Diego, CA 92121, USA.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper y Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: